Advertisement
Research Article| Volume 54, ISSUE 4, P18-21, August 13, 1984

Pharmacology of lorcainide

  • Deborah L. Keefe
    Correspondence
    Address for reprints: Deborah L. Keefe, MD, Bronx Municipal Hospital Center, Bldg. J, Room 5E5, Pelham Parkway South and Eastchester Road, Bronx, New York 10461.
    Affiliations
    From the Cardiology Division, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York USA
    Search for articles by this author
DOI:https://doi.org/10.1016/0002-9149(84)90819-1
Pharmacology of lorcainide
Previous ArticleNew directions in antiarrhythmic drug therapy
Next ArticleLorcainide for high-frequency ventricular arrhythmia: Preliminary results of a short-term double-blind and placebo-controlled crossover study and long-term follow-up
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Lorcainide is a new type 1 antiarrhythmic drug that is well absorbed orally, with bioavailability increasing with both dose and continued administration. It is metabolized through the liver, and patients with significant liver disease will require dosage reduction. The drug has an active metabolite, norlorcainide, whose activity is similar to that of lorcalnide but whose half-life Is 26 hours instead of 8 for the parent compound. The levels of this metabolite are nearly twice those of lorcalnide at steady state. The long half-life of the metabolite and the changing bioavailability of lorcalnide require that a given dose be administered for 1 week for the maximum effect to be demonstrated.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Carmellet E
        • Janssen P.A.J.
        • Marsboom R
        • Van Neuten J.M.
        • Nhonneun R
        Antiarrhythmic etectrophysiologic and hemodynamic effects of lorcainide.
        Arch Int Pharamcodyn Ther. 1978; 231: 104-130
        • Aimotrefl A.A.
        • Baker J.B.E.
        Antifibrillatory efficacy of encainide, lorcainide and ORG 6001 compared with lignocaine in isolated hearts of rabbits and guinea pigs.
        Br J Pharmacol. 1981; 73: 373-377
        • Meinertz T
        • Kersting F
        • Kasper W
        • Just H
        • Bechtold H
        • Jähnchen E
        Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease.
        Eur J Clin Pharmacol. 1980; 18: 461-465
        • Shlta A
        • Bernard R
        • Mostinckx R
        • Debacker M
        Haemodynamic reactions after intravenous injection of lorcainide hydrochloride in acute myocardial infarction.
        Eur J Cardiol. 1981; 12: 237-242
        • Carmellot E
        • Zaman N.Y.
        Comparative effects of lignocaine and lorcainide on conduction in the Langendorff-perfused guinea pig heart.
        Cardiovasc Res. 1979; 13: 439-449

      6. Keefe DL, Kates RE, Winkle RA. Comparative electrophysiology of lorcainide and norlorcainide in the dog. J Cardiovasc Pharmacol, in press.

        • Saksena S
        • Rothbert S.T.
        • Cappello G
        • Bernstein A
        • Somanl P
        Clinical and electrophysiologic effects of chronic lorcainide therapy in refractory ventricular tachycardia.
        J Am Coll Cardiol. 1983; 2: 538-544
        • Echt D.S.
        • Mitchell L.B.
        • Kates R.E.
        • Winkle R.A.
        Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
        Circulation. 1983; 68: 392-399
        • Bär F.W.
        • Farré J
        • Ross D
        • Vanagt E.J.
        • Gorgels A.P.
        • Wellens H.J.J.
        Electrophysiological effects of lorcainide, a new antiarrhythmic drug.
        Br Heart J. 1981; 45: 292-298
        • Kasper W
        • Meinertz T
        • Kersting F
        • Löllgen H
        • Lang K
        • Just H
        Electrophysiologic actions of lorcainide in patients with cardiac disease.
        J Cardiovasc Pharmacol. 1979; 1: 343-352
        • Gstöttner N
        • Gmeiner R
        Cardiac electrophysiological effects of lorcainide in man.
        Eur J Clin Pharmacol. 1979; 15: 241-247
        • Woestenborghs R
        • Michiels M
        • Heykants J
        Simultaneous gas chromatographic determination of lorcainide hydrochloride and three of its principal metabolites in biological samples.
        J Chromatogr. 1979; 164: 169-176
        • Klotz U
        • Müller-Seydlitz P
        • Heimburg P
        Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent.
        Clin Pharmacokinet. 1978; 3: 407-418
        • Yee Y.G.
        • Kates R.E.
        High performance liquid chromatographic analysis of lorcainide and its active metabolite, norlorcainide, in human plasma.
        J Chromatogr. 1981; 223: 454-459
        • Jähnchen E
        • Bechtold H
        • Kasper W
        • Kersting F
        • Just H
        • Keykants J
        • Meinertz T
        Lorcainide kinetics.
        Clin Pharmacol Ther. 1979; 26: 187-204
        • Kates R.E.
        • Keefe D.L.
        • Winkle R.A.
        Lorcainide disposition kinetics in arrhythmia patients.
        Clin Pharmacol Ther. 1983; 33: 28-34
        • Klotz U
        • Fischer C
        • Müller-Seydlitz P
        • Schuitz J
        • Müller W.A.
        Alterations in the disposition of differently cleared drugs in patients with cirrhosis.
        Clin Pharmacol Ther. 1979; 26: 221-227
        • Klotz U
        • Müller-Seydlitz P
        • Heimburg P
        Disposition and antiarrhythmic effect of lorcainide.
        Int J Clin Pharmacol Biopharm. 1979; 17: 152-158
        • Winkle R.A.
        • Keefe D.L.
        • Rodrlgues I
        • Kates R.E.
        Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
        Am J Cardiol. 1984; 53: 544-551
        • Klotz U
        • Golbs E
        The pharmacokinetics and tissue distribution of the new antiarrhythmic agent lorcainide (R15889) in rats.
        Arzneim-Forsch/Drug Res. 1980; 30: 619-621
        • Amery W.K.
        • Heykants J.J.P.
        • Xhonneux R
        • Towse G
        • Oettel P
        • Gough D.A.
        • Janssen P.A.J.
        Lorcainide, a first review.
        Acta Cardiol. 1981; 36: 207-234
        • Wagner J.G.
        A safe method for rapidly achieving plasma concentration plateaus.
        Clin Pharmacol Ther. 1974; 16: 691-700
        • Meinertz T
        • Kasper W
        • Kersting F
        • Just H
        • Bechtold H
        • Jähnchen E
        Lorcainide kinetics and dynamics.
        Clin Pharmacol Ther. 1979; 26: 196-204
        • Keefe D.L.
        • Peters F
        • Winkle R.A.
        Randomized double-blind placebo controlled crossover trial documenting oral lorcainide efficacy in suppression of symptomatic ventricular tachyarrhythmias.
        Am Heart J. 1982; 103: 511-518
        • Vaughan Williams E.M.
        A classification of antiarrhythmic actions reassessed after a decade of new drugs.
        J Clin Pharmacol. 1984; 24: 129-147
        • Keefe D.L.
        • Kates R.E.
        • Harrison D.C.
        New antiarrhythmic drugs: their place in therapy.
        Drugs. 1981; 22: 363-400

      Article info

      Identification

      DOI: https://doi.org/10.1016/0002-9149(84)90819-1

      Copyright

      © 1984 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX